Live Report · Updated February 9, 2026

AbbVie vs Bristol Myers Squibb

This page provides a neutral comparison of AbbVie and Bristol Myers Squibb, examining their distinct business models, recent financial performance, and current market context. Gain insight into key aspects influencing each company's position within the pharmaceutical industry, presented factually to aid understanding. Educational content, not financial advice.

This page provides a neutral comparison of AbbVie and Bristol Myers Squibb, examining their distinct business models, recent financial performance, and current market context. Gain insight into key as...

Comparison Snapshot

Key Financial Metrics

ABBV

Metric

BMY

$394.59B

Market Cap

$123.71B

10.25%

Potential Profit

-12.48%

Buy

Analyst Rating

Hold

Why It's Moving

AbbVie Crushes Q4 Earnings and Lifts 2026 Outlook, Yet Shares Dip on Mixed Signals

Q4 revenues surged 10% year-over-year to beat forecasts, highlighting strength in key immunology franchises that are offsetting Humira erosion.
Upbeat 2026 EPS outlook exceeded consensus, driven by sales momentum in newer drugs like Skyrizi and a rebounding aesthetics portfolio.
Positive pipeline updates on upadacitinib for atopic dermatitis and ABBV-932 for bipolar disorder bolster long-term revenue potential.

Sentiment:

🐃Bullish

BMY Stock Warning: Why Analysts See -7% Downside Risk

Q4 earnings drove a 7.6% stock surge to $61.99 on Feb. 6, but projected 2026 revenues of $46-47.5B signal a drop from 2025's $48.2B due to generic erosion on key products.
U.S. government pricing deal provides free Eliquis to Medicaid from Jan. 2026 and 80% discounts on drugs like Sotyktu, squeezing margins while aiming to bolster supply resilience.
Pipeline approvals, $2B cost savings target by 2027, and new AI collaboration with Evinova highlight growth potential, yet analysts urge caution on valuation amid these offsets.

Sentiment:

🐻Bearish

AbbVie Crushes Q4 Earnings and Lifts 2026 Outlook, Yet Shares Dip on Mixed Signals

Q4 revenues surged 10% year-over-year to beat forecasts, highlighting strength in key immunology franchises that are offsetting Humira erosion.
Upbeat 2026 EPS outlook exceeded consensus, driven by sales momentum in newer drugs like Skyrizi and a rebounding aesthetics portfolio.
Positive pipeline updates on upadacitinib for atopic dermatitis and ABBV-932 for bipolar disorder bolster long-term revenue potential.

Sentiment:

🐃Bullish

BMY Stock Warning: Why Analysts See -7% Downside Risk

Q4 earnings drove a 7.6% stock surge to $61.99 on Feb. 6, but projected 2026 revenues of $46-47.5B signal a drop from 2025's $48.2B due to generic erosion on key products.
U.S. government pricing deal provides free Eliquis to Medicaid from Jan. 2026 and 80% discounts on drugs like Sotyktu, squeezing margins while aiming to bolster supply resilience.
Pipeline approvals, $2B cost savings target by 2027, and new AI collaboration with Evinova highlight growth potential, yet analysts urge caution on valuation amid these offsets.

Sentiment:

🐻Bearish

Investment Analysis

AbbVie

ABBV

Pros

AbbVie maintains dominant market position in immunology with Skyrizi and Rinvoq driving robust revenue growth.
Strong balance sheet supports sustained R&D investment and share repurchases amid patent cliffs.
Humira successors demonstrate high-teens growth potential offsetting legacy product declines.

Considerations

Ongoing patent expirations for key drugs expose revenue to generic erosion through 2028.
Regulatory hurdles in obesity portfolio delay potential new growth catalysts.
High debt levels from past acquisitions elevate financial risk in rising interest environment.

Bristol Myers Squibb

BMY

Pros

Growth products like Eliquis, Reblozyl and Breyanzi deliver strong double-digit sales increases into 2026.
Attractive 4.5% dividend yield backed by 56-year payment history and recent hikes.
Pipeline catalysts in 2026 offer substantial upside potential beyond priced-in LOE headwinds.

Considerations

Legacy portfolio faces 15-17% revenue decline in 2025 from generic competition.
Loss of exclusivity pressures persist through 2028 with $20-30 billion revenue impact.
Sell-side consensus holds 'Hold' rating despite recent upgrades amid execution uncertainties.

Related Market Insights

Beyond The Patent Cliff: Pharma's New Growth Engines

Discover how pharma companies like AbbVie thrive beyond patent cliffs with new blockbusters. Explore investment opportunities in resilient drugmakers with strong pipelines. Invest from £1.